A national mortality trend can identify a major public-health pattern without showing how two drugs entered an individual person’s body. Hoopsick and Yockey’s 2023 analysis found increasing opioid co-involvement in deaths classified as methamphetamine-related. Understanding the coding method is essential before interpreting its percentages as chemical or causal proof.
What records did the researchers analyze?
The study used CDC WONDER multiple-cause death-certificate data for U.S. residents aged 15–74 from 1999 through 2021. Data through 2020 were final; 2021 data were provisional when analyzed. This is a historical descriptive epidemiologic study, not an experiment or a new laboratory analysis of retained specimens.
The authors selected poisoning deaths across specified intent categories, then used ICD-10 code T43.6, “psychostimulants with abuse potential,” to operationalize methamphetamine-related deaths. The title’s methamphetamine label therefore rests on a coded psychostimulant category. The method does not present an individually measured methamphetamine concentration for every record.
How was opioid co-involvement defined?
The analysis used T40.1 for heroin and T40.4 for other synthetic narcotics, described in the paper in relation to fentanyl and its analogs. These are categories in a mortality database. Their presence in a coded record is different from a standardized assay identifying one exact synthetic opioid in one specified specimen.
A transparent account preserves the authors’ operational terminology while explaining the category boundaries. Substituting “laboratory-confirmed methamphetamine plus illicit fentanyl in every case” would claim more specificity than this dataset supplies.
What did the historical trends show?
The selected records included 135,433 deaths across the period, with heroin or synthetic-narcotic co-involvement in 42.8% overall. The annual proportion with that co-involvement reached 61.2% in 2021. The overall-period percentage and the last-year percentage describe different denominators and should not be interchanged.
The reported age-adjusted mortality rate increased from 0.27 per 100,000 population in 1999 to 13.93 in 2021. A population mortality rate is not the probability that a person who uses methamphetamine will die: the study did not measure the number of exposed people or their individual doses as its denominator.
Does co-involvement identify contamination?
No. Intentional co-use, unintentional exposure and other circumstances may all be compatible with co-involvement in mortality records. The study did not test purchased drug products, interview every decedent or determine a verified sequence and route of administration.
Nor can an aggregate association assign the relative causal contribution of each detected substance in a particular death. That question requires the individual investigation, including specimen findings, medical history, scene evidence and competing explanations. Population data help frame a question; they do not perform that reconstruction.
What can affect the counts?
The authors noted exclusions of nonresidents and deaths without relevant toxicology or drug-specific information, as well as reporting lags in provisional 2021 data. Differences in testing and certification can influence which drugs appear in the coded record. Missing drug information should not be silently treated as proof that a substance was absent.
The study supports concern about a rising overlap between stimulant-coded and opioid-coded fatal poisonings during its observation period. Its practical value depends on retaining the age range, historical dates, coding definitions and uncertainty about exposure circumstances. The reported 2021 peak is not a statement about present-day rates.
Source
Hoopsick RA, Yockey RA. Methamphetamine-Related Mortality in the United States: Co-Involvement of Heroin and Fentanyl, 1999–2021. American Journal of Public Health. 2023;113(4):416–419. doi:10.2105/AJPH.2022.307212.
Leave a Reply